Mucosal Immune Responses Against an Oral Enterotoxigenic Escherichia coli Vaccine Evaluated in Clinical Trials. (22nd September 2021)

• Record Type: Journal Article
• Authors: Svennerholm, Ann-Mari; Lundgren, Anna; Leach, Susannah; Akhtar, Marjahan; Qadri, Firdausi
• Is Part Of: Journal of infectious diseases. Volume 224:Supplement 7(2021)
• Page Start: S821
• Page End: S828
• Publication Date: 2021-09-22
• Subjects: ETEC -- mucosal immune responses -- vaccine; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiab475
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: Enterotoxigenic Escherichia coli (ETEC) is a leading cause of mortality and morbidity in children in low-income countries. We have tested an oral ETEC vaccine, ETVAX, consisting of inactivated E coli overexpressing the most prevalent colonization factors and a toxoid, LCTB A, administered together with a mucosal adjuvant, double-mutant heat-labile toxin (dmLT), for capacity to induce mucosal immune responses and immunological memory against the primary vaccine antigens, ie, colonization factors, heat-labile toxin B-subunit and O antigen. The studies show that ETVAX could induce strong intestine-derived and/or fecal immune responses in a majority of vaccinated Swedish adults and in different age groups, including infants, in Bangladesh.